| Literature DB >> 30227471 |
Nicole Sheetz1, Brett Wilson2, Joanne Benedict3, Esther Huffman4, Andy Lawton5, Mark Travers6, Patrick Nadolny7, Stephen Young8, Kyle Given9, Lawrence Florin10.
Abstract
TransCelerate has developed a risk-based monitoring methodology that transforms clinical trial monitoring from a model rooted in source data verification (SDV) to a comprehensive approach leveraging cross-functional risk assessment, technology, and adaptive on-site, off-site, and central monitoring activities to ensure data quality and subject safety. Evidence suggests that monitoring methods that concentrate on what is critical for a study and a site may produce better outcomes than do conventional SDV-driven models. This article assesses the value of SDV in clinical trial monitoring via a literature review, a retrospective analysis of data from clinical trials, and an assessment of major and critical findings from TransCelerate member company internal audits. The results support the hypothesis that generalized SDV has limited value as a quality control measure and reinforce the value of other risk-based monitoring activities.Entities:
Keywords: data integrity; quality control; risk-based monitoring; source data review; source data verification
Year: 2014 PMID: 30227471 DOI: 10.1177/2168479014554400
Source DB: PubMed Journal: Ther Innov Regul Sci ISSN: 2168-4790 Impact factor: 1.778